Burnaska David R, Huang Grant D, O'Leary Timothy J
Cooperative Studies Program, Office of Research and Development, Veterans Health Administration, Washington DC, 20420, USA.
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Contemp Clin Trials Commun. 2021 Jul 9;23:100811. doi: 10.1016/j.conctc.2021.100811. eCollection 2021 Sep.
The process by which funding organizations select among the myriad number of proposals they receive is a matter of significant concern for researchers and the public alike. Despite an extensive literature on the topic of peer review and publications on criteria by which clinical investigations are reviewed, publications analyzing peer review and other processes leading to government funding decisions on large multi-site clinical trials proposals are sparse. To partially address this gap, we reviewed the outcomes of scientific and programmatic evaluation for all letters of intent (LOIs) received by the Department of Veterans Affairs (VA) Cooperative Studies Program (CSP) between July 4, 2008, and November 28, 2016. If accepted, these LOIs represented initial steps towards later full proposals that also underwent scientific peer review. Twenty-two of 87 LOIs were ultimately funded and executed as CSP projects, for an overall success rate of 25%. Most proposals which received a negative decision did so prior to submission of a full proposal. Common reasons for negative scientific review of LOIs included investigator inexperience, perceived lack of major scientific impact, lack of preliminary data and flawed or confused experimental design, while the most common reasons for negative reviews of final proposals included questions of scientific impact and issues of study design, including outcome measures, randomization, and stratification. Completed projects have been published in high impact clinical journals. Findings highlight several factors leading to successfully obtaining funding support for clinical trials. While our analysis is restricted to trials proposed for CSP, the similarities in review processes with those employed by the National Institutes of Health and the Patient Centered Outcomes Research Institute suggest the possibility that they may also be important in a broader context.
资助机构在收到的大量提案中进行筛选的过程,是研究人员和公众都极为关注的问题。尽管关于同行评审这一主题以及临床研究评审标准的文献颇为丰富,但分析同行评审以及其他导致政府对大型多中心临床试验提案做出资助决定的过程的出版物却寥寥无几。为了部分填补这一空白,我们回顾了退伍军人事务部(VA)合作研究项目(CSP)在2008年7月4日至2016年11月28日期间收到的所有意向书(LOI)的科学和项目评估结果。如果这些意向书被接受,它们代表了迈向后续也会接受科学同行评审的完整提案的初步步骤。87份意向书中有22份最终获得资助并作为CSP项目得以实施,总体成功率为25%。大多数收到否定决定的提案是在提交完整提案之前就被否定了。对意向书进行负面科学评审的常见原因包括研究者缺乏经验、被认为缺乏重大科学影响力、缺乏初步数据以及实验设计存在缺陷或混乱,而对最终提案进行负面评审的最常见原因包括科学影响力问题以及研究设计问题,包括结果测量、随机化和分层。已完成的项目已发表在高影响力的临床期刊上。研究结果突出了几个有助于成功获得临床试验资助支持的因素。虽然我们的分析仅限于为CSP提议的试验,但与美国国立卫生研究院和以患者为中心的结果研究机构所采用的评审过程的相似性表明,在更广泛的背景下它们可能也很重要。